Cellectar Biosciences, Inc. Logo

Cellectar Biosciences, Inc.

Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.

CLRB | US

Overview

Corporate Details

ISIN(s):
US15117F8077
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, 7932 FLORHAM PARK

Description

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectar Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectar Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectar Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CG Invites Co., Ltd. Logo
A biopharmaceutical company specializing in digital genomics and personalized medicine.
South Korea
083790
CG Oncology, Inc. Logo
Develops bladder-sparing oncolytic immunotherapies for urologic cancers.
United States of America
CGON
CHA Vaccine Research Institute Logo
Develops vaccines and immunotherapeutics using proprietary adjuvant platforms.
South Korea
261780
Develops and manufactures veterinary medicines and functional feed additives.
South Korea
052670
Chemical Works of Gedeon Richter Plc Logo
Vertically integrated pharma company focused on women's health and other therapies.
Hungary
RICHT
Chemomab Therapeutics Ltd. Logo
Clinical-stage biotech developing therapeutics for fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and markets prescription, OTC, and nutritional products.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, develops, manufactures, and sells traditional Chinese medicine products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Develops, manufactures, and sells pharmaceutical products and health supplements.
South Korea
034940
Chong Kun Dang Pharmaceutical Corp. Logo
Develops and manufactures drugs for systemic anti-infectives and metabolic diseases.
South Korea
185750

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.